Establishment Labs Launches JOY™
JOY includes the Motiva Woman’s Choice Program™. This first-of-its-kind program allows women with JOY, subject to certain terms and conditions, to receive financial support from
The Motiva Ergonomix2 implants included with JOY offer all the proven benefits of Establishment Labs’ industry leading Ergonomix® implants, including SmoothSilk® surface technology, ProgressiveGel® Ultimate, and RFID enablement, as well as several new technologies, including Motiva SuperSilicones®, TrueMonobloc+™, and BluSeal+®. These advances offer enhanced ergonomy, extra soft feel, and more natural movement. Motiva Ergonomix2 implants are available exclusively through the JOY program.
“JOY is the embodiment of Establishment Labs’ commitment to support women in their breast aesthetics journey with advanced technologies and an exceptional experience,” said Juan José Chacón-Quirós, Founder and Chief Executive Officer of
Plastic surgeons in the JOY program may receive specialized medical education that includes training on optimizing outcomes and reducing complications and on specialized techniques, like Motiva MinimalScar® and MotivaHybrid®. Women interested in JOY can find additional information and be connected to qualified surgeons at https://motiva.health/patients-motiva-joy.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on